



3 December 2024

ASX Announcement

**DATE OF EXTRAORDINARY GENERAL MEETING (SPILL MEETING)
AND CLOSING DATE FOR DIRECTOR NOMINATIONS**

MELBOURNE Australia, 3 December 2024: Island Pharmaceuticals Ltd (**ASX: ILA**) (**Company**) confirms that at its Annual General Meeting held on 19 November 2024, the Company received a second strike with respect to its remuneration report and the spill resolution was passed by the Company's shareholders. Accordingly, the Company intends to hold an extraordinary general meeting of shareholders (**Spill Meeting**) at: 11:00 am (AEDT) on Tuesday 28 January 2025, at K&L Gates 31/1 O'Connell St Sydney NSW 2000.

A notice of meeting for the Spill Meeting will be announced to the ASX and provided to Shareholders in due course.

The closing date for the receipt of nominations for the election of Directors is 10 December 2024.

--ends--

The release of this announcement was authorised by CEO and Managing Director, David Foster.

For further information, please contact:

David Foster
Managing Director
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au



About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.